Autologous blood or platelet-rich plasma injections

Platelet-rich plasma (PRP) and whole blood injections are treatments that have been utilized for a variety of healing applications in sports medicine and orthopedic medicine.

Platelet-rich plasma was first reviewed by the HTA program in 2016

  • In 2022, the HCA director selected platelet-rich plasma (PRP) for rereview for osteoarthritis treatment based on published evidence that could change the original coverage determination.

Status: Decision completed

Why is PRP being reviewed?

Platelet-rich plasma (PRP) and whole blood injections are proposed for a variety of healing applications. Concerns are considered medium for safety, medium/high for efficacy, and medium for cost-effectiveness.

Primary criteria ranking

  • Safety = Medium
  • Efficacy = Medium/High
  • Cost = Medium

Documentation

Assessment timeline

  • Draft key questions published: October 13, 2022
    • Public comment period: October 13 to 27, 2022
  • Final key questions published: November 29, 2022
  • Draft report published: May 11, 2023
    • Public comment period: May 11 to June 12, 2023
  • Final report published: June 26, 2023
  • HTCC public meeting: July 21, 2023
  • Draft findings and decision published: July 27, 2023
    • Public comment period: July 27 to August 10, 2023
  • Final findings and decision published: November 20, 2023

 

All future dates are estimates and subject to change.